Objective: Retrograde in situ laser fenestration of the left subclavian artery (LSA) or common carotid artery during emergent thoracic endovascular aortic repair (TEVAR) is an innovative method to revascularize arch branches for diverse thoracic aortic diseases. This study provides an update on our expanded experience with extended follow-up to determine the efficiency and durability of this technique.
Methods: Patients who underwent TEVAR with aortic arch branch revascularization from 2009 through 2018 were retrospectively reviewed. After TEVAR, the endograft was deployed over a branch orifice, in situ retrograde laser fenestration was performed through retrograde access, and a balloon-expandable covered stent was deployed in the LSA or common carotid artery. Postoperative imaging with computed tomography angiography was performed to assess branch patency, endoleaks, and fenestration-related reinterventions.
Results: TEVAR with laser fenestration was successfully performed in 60 patients (38 men; mean age, 61 years) in an urgent or emergent setting for diverse thoracic aortic diseases including 16 ruptures. Seventeen had acute complicated type B aortic dissection, 15 had intramural hematoma, and 17 had chronic dissection. TEVAR was done in zone 0 in 2 patients, in zone 1 in 7 patients, and in zone 2 in 51 patients. A balloon-expandable covered stent was placed across the fenestration into 56 LSAs, 3 left coronary arteries, and 1 right coronary artery. Mean length of stay was 9 days. Mean follow-up was 2.44 years. In-hospital mortality was 8.3%. Stroke rate was 3.3% (2/60), and three had permanent paraplegia. Follow-up computed tomography angiography demonstrated 100% primary patency of branch stents. There was no type III endoleak, but three type IC endoleaks required early coiling (one) and late restenting (two) for a 5.45% fenestration-related major reintervention rate.
Conclusions: In situ retrograde laser fenestration is a rapid, effective, and durable method to revascularize arch branches during emergent TEVAR. The high technical success, low fenestration-related morbidity and reintervention rate, and excellent branch stent patency support use of this versatile technique. Objective: The role of nonoperative management of blunt traumatic thoracic aortic injury (BTAI) continues to evolve. Our objective was to summarize the growing body of literature on this practice.
Methods: A systematic search of PubMed and Embase was completed to identify original articles reporting retrospective or prospective primary data on BTAI patients managed without surgical intervention during their index hospitalization. Articles meeting inclusion criteria were selected on the basis of abstract and full-text screening. Study selection and data abstraction were performed in duplicate, with discrepancies resolved by a third reviewer.
Results: Of 2162 identified studies, 74 were included and reported on 8606 BTAI patients who were managed nonoperatively between 1970 and 2016. Only one study was prospective. The median nonoperative sample size was 11 patients. Characterization of injury grade differed across studies, and injuries to the ascending aorta or aortic arch were often included in outcome summaries. Follow-up varied widely from 1 day to 8 years. Among the 59 studies with information on injury grade (n ¼ 1250 patients), injury healing or improvement on follow-up imaging was reported in 226 patients (18%), who mostly had intimal tears. Injury progression or requirement of a subsequent procedure was reported in 69 patients (5.5%), along with 37 aorta-related deaths (16%).
Conclusions: An increasing number of reports support nonoperative management of intimal tears, consistent with Society for Vascular Surgery guidelines. However, retrospective interpretation of the intention of treatment, heterogeneous injury characterization, and variable follow-up remain major limitations to the informed use of nonoperative management across all BTAI grades.
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